Orchestrating the Parkinson’s disease microenvironment in 3D for pathogenesis study and therapeutic development
Source abstract
Abstract
Abstract The incidence of Parkinson’s disease (PD) has been steadily increasing globally, while traditional two-dimensional cell cultures and animal models face significant challenges in effectively elucidating its complex pathological mechanisms and screening potential drugs. Advanced in vitro models that incorporate patient-specific characteristics and three-dimensional (3D) microenvironments have emerged as powerful alternatives. This review first outlines current perspectives on PD etiology and pathogenesis, highlighting their implications for 3D modeling systems. A systematic comparison evaluates organoid, microfluidic, and 3D bioprinting platforms by leveraging their recent applications in PD mechanistic studies and therapeutic screening. The utilization of these cutting-edge technologies in PD model development not only deepens mechanistic insights but also streamlines therapeutic innovation, paving the way for effective treatments against this debilitating neurodegenerative disorder.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Pluripotent Stem Cells Research · Neuroscience and Neural Engineering
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The epidemiology of Parkinson’s disease10.1016/S0140-6736(23)01419-8 ↗
2. Global, regional and national temporal trends in Parkinson’s disease incidence, disability-adjusted life year rates in middle-aged and older adults: a cross-national inequality analysis and Bayesian age-period-cohort analysis based on the global burden of disease 202110.1007/s10072-024-07941-7 ↗
3. The Parkinson pandemic—a call to action10.1001/jamaneurol.2017.3299 ↗
4. New insights into the complex role of mitochondria in Parkinson’s disease10.1016/j.pneurobio.2018.09.003 ↗
5. Oxidative stress and dopaminergic metabolism: a major PD pathogenic mechanism and basis of potential antioxidant therapies10.2174/1871527322666230609141519 ↗
6. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction10.1038/s41419-023-05672-9 ↗
7. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases10.1186/s12974-022-02584-x ↗
8. Non-cell-autonomous neurotoxicity of α-synuclein through microglial Toll-like Receptor 210.5607/en.2016.25.3.113 ↗
9. Non-cell-autonomous neurotoxicity in Parkinson’s disease mediated by astroglial α-Synuclein10.1016/j.stemcr.2019.01.011 ↗
10. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease10.1038/s41591-024-02886-y ↗
11. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease10.1126/scitranslmed.abj2658 ↗
12. Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues10.1016/j.pharmthera.2023.108419 ↗
13. PINK1 kinase dysfunction triggers neurodegeneration in the primate brain without impacting mitochondrial homeostasis10.1007/s13238-021-00888-x ↗
14. Conserved cell types with divergent features in human versus mouse cortex10.1038/s41586-019-1506-7 ↗
15. Effects of extracellular matrix viscoelasticity on cellular behaviour10.1038/s41586-020-2612-2 ↗
16. A 3D human co-culture to model neuron-astrocyte interactions in tauopathies10.1186/s12575-023-00194-2 ↗
17. Modeling cell-cell interactions in the brain using cerebral organoids10.1016/j.brainres.2019.146458 ↗
18. “ECM”: its nature, origin and function in cell aggregation10.1016/0014-4827(63)90299-4 ↗
19. Substrate mechanics and cell spreading10.1016/0014-4827(91)90406-K ↗
20. Hydrophilic gels for biological use10.1038/185117a0 ↗
21. 6-hydroxy-dopamine induced degeneration of central monoamine neurons10.1016/0014-2999(68)90164-7 ↗
22. From cell lines to pluripotent stem cells for modelling Parkinson’s disease10.1016/j.jneumeth.2020.108741 ↗
23. Induction of pluripotent stem cells from adult human fibroblasts by defined factors10.1016/j.cell.2007.11.019 ↗
24. Cerebral organoids model human brain development and microcephaly10.1038/nature12517 ↗
25. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription10.1016/j.cell.2013.11.009 ↗
26. A microfluidic-based neurotoxin concentration gradient for the generation of an in vitro model of Parkinson’s disease10.1063/1.3580756 ↗
27. Cell and organ printing 1: protein and cell printers10.1002/ar.a.10057 ↗
28. 3D printing of layered brain-like structures using peptide modified gellan gum substrates10.1016/j.biomaterials.2015.07.022 ↗
29. A Parkinson’s disease model composed of 3D bioprinted dopaminergic neurons within a biomimetic peptide scaffold10.1088/1758-5090/ac7eec ↗
30. Parkinson’s disease and the environment10.3389/fneur.2019.00218 ↗
31. The pathogenesis of Parkinson’s disease10.1016/S0140-6736(23)01478-2 ↗
32. Parkinson’s disease: etiology, neuropathology, and pathogenesis
33. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease10.1093/brain/awt192 ↗
34. Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder10.1080/00207454.2018.1486837 ↗
35. Increased ATP release and higher impact of adenosine A2A receptors on corticostriatal plasticity in a rat model of presymptomatic Parkinson’s disease10.1007/s12035-022-03162-1 ↗
36. Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson’s disease model10.1038/s41531-024-00777-0 ↗
37. Neuropathology of α-synuclein in Parkinson’s disease10.1111/neup.12812 ↗
38. Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue10.1038/s41467-024-46832-5 ↗
39. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals10.1038/s41593-025-01910-9 ↗
40. Aggregate-prone brain regions in Parkinson’s disease are rich in unique N-terminus α-synuclein conformers with high proteolysis susceptibility10.1038/s41531-023-00614-w ↗
41. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration10.1073/pnas.1913904117 ↗
42. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes10.1038/s41593-019-0423-2 ↗
43. The cell biology of Parkinson’s disease10.1083/jcb.202012095 ↗
44. Bioengineered models of Parkinson’s disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment10.1007/s00018-021-04047-7 ↗
45. A matrigel-based 3D construct of SH-SY5Y cells models the α-synuclein pathologies of Parkinson’s disease10.1242/dmm.049125 ↗
46. Down-regulation of platelet-derived growth factor receptor β in pericytes increases blood-brain barrier permeability and significantly enhances α-synuclein in a Parkinson’s disease 3D cell model in vitro under hyperglycemic condition10.1016/j.tice.2025.102751 ↗
47. Modeling Parkinson’s disease pathology in human dopaminergic neurons by sequential exposure to α-synuclein fibrils and proinflammatory cytokines10.1038/s41593-024-01775-4 ↗
48. Re-examining the pathobiological basis of gait dysfunction in Parkinson’s disease10.1016/j.tins.2025.01.002 ↗
49. Synaptic dysfunction and extracellular matrix dysregulation in dopaminergic neurons from sporadic and E326K-GBA1 Parkinson’s disease patients10.1038/s41531-024-00653-x ↗
50. Upregulated ECM genes and increased synaptic activity in Parkinson’s human DA neurons with PINK1/ PRKN mutations10.1038/s41531-024-00715-0 ↗
51. Lewy body–like Inclusions in human midbrain organoids carrying glucocerebrosidase and α-synuclein mutations10.1002/ana.26166 ↗
52. Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson’s disease10.1016/j.mcn.2024.103919 ↗
53. Parkinson’s disease modeling using directly converted 3D induced dopaminergic neuron organoids and assembloids10.1002/advs.202412548 ↗
54. 3D cultures of Parkinson’s disease-specific dopaminergic neurons for high content phenotyping and drug testing10.1002/advs.201800927 ↗
55. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson’s disease10.1038/s41467-023-39038-8 ↗
56. Modeling G2019S-LRRK2 sporadic Parkinson’s disease in 3D midbrain organoids10.1016/j.stemcr.2019.01.020 ↗
57. Modeling Parkinson’s disease in midbrain-like organoids10.1038/s41531-019-0078-4 ↗
58. Parkinson’s disease phenotypes in patient neuronal cultures and brain organoids improved by 2-hydroxypropyl-β-cyclodextrin treatment10.1002/mds.28810 ↗
59. Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model10.1038/s41467-024-44732-2 ↗
60. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism10.1038/s41467-023-37454-4 ↗
61. Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids10.1093/brain/awae365 ↗
62. Neurodevelopmental defects and neurodegenerative phenotypes in human brain organoids carrying Parkinson’s disease-linked DNAJC6 mutations10.1126/sciadv.abb1540 ↗
63. Gene–environment interactions for Parkinson’s disease10.1002/ana.26852 ↗
64. Etiology and pathogenesis of Parkinson’s disease10.1002/mds.23732 ↗
65. Epidemiology of Parkinson’s disease: an update10.1007/s11910-024-01339-w ↗
66. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor?10.1016/j.arr.2014.01.004 ↗
67. Uncovering the role of natural and synthetic small molecules in counteracting the burden of α-synuclein aggregates and related toxicity in different models of Parkinson’s disease10.3390/ijms241713370 ↗
68. Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils10.1073/pnas.2217835120 ↗
69. Enhanced mTORC1 signaling and protein synthesis in pathologic α-synuclein cellular and animal models of Parkinson’s disease10.1126/scitranslmed.add0499 ↗
70. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease10.1126/scitranslmed.abp9352 ↗
71. Human tripartite cortical network model for temporal assessment of alpha-synuclein aggregation and propagation in Parkinson’s disease10.1038/s41531-024-00750-x ↗
72. The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson’s disease10.1371/journal.pbio.3002974 ↗
73. Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson’s disease10.1016/j.xcrm.2025.101999 ↗
74. Oxidative stress and aging as risk factors for Alzheimer’s disease and Parkinson’s disease: the role of the antioxidant melatonin10.3390/ijms24033022 ↗
75. Vitamin B12 ameliorates the pathological phenotypes of multiple Parkinson’s disease models by alleviating oxidative stress10.3390/antiox12010153 ↗
76. Neuroprotective effects of morroniside from Cornus officinalis sieb. Et zucc against Parkinson’s disease via inhibiting oxidative stress and ferroptosis10.1186/s12906-023-03967-0 ↗
77. Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01353-3 ↗
78. Mitochondrial dysfunction in Parkinson’s disease—a key disease hallmark with therapeutic potential10.1186/s13024-023-00676-7 ↗
79. Ameliorating mitochondrial dysfunction for the therapy of Parkinson’s disease10.1002/smll.202311571 ↗
80. Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss10.1093/brain/awaf051 ↗
81. Brain organoid as a model to study the role of mitochondria in neurodevelopmental disorders: achievements and weaknesses10.3389/fncel.2024.1403734 ↗
82. Inflammation and immune dysfunction in Parkinson disease10.1038/s41577-022-00684-6 ↗
83. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease10.1016/j.nbd.2017.04.004 ↗
84. The role of Toll-like receptors and neuroinflammation in Parkinson’s disease10.1186/s12974-022-02496-w ↗
85. Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease10.1038/s41467-023-39060-w ↗
86. The Parkinson’s disease-associated LRRK2-G2019S variant restricts serine metabolism, leading to microglial inflammation and dopaminergic neuron degeneration10.1186/s12974-025-03577-2 ↗
87. Brain organoid models for studying the function of iPSC-derived microglia in neurodegeneration and brain tumours10.1016/j.nbd.2024.106742 ↗
88. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease10.1186/s12964-023-01402-y ↗
89. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders10.1038/s41583-022-00641-1 ↗
90. The role of astrocyte dysfunction in Parkinson’s disease pathogenesis10.1016/j.tins.2017.04.001 ↗
91. Neurotoxic reactive astrocytes are induced by activated microglia10.1038/nature21029 ↗
92. Patient-specific iPSC-derived astrocytes contribute to non-cell-autonomous neurodegeneration in Parkinson’s disease10.1016/j.stemcr.2018.12.011 ↗
93. Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson’s disease10.1073/pnas.2110746119 ↗
94. Mitochondrial glutamine transporter SLC1A5_var, a potential target to suppress astrocyte reactivity in Parkinson’s disease10.1038/s41419-022-05399-z ↗
95. Alleviating symptoms of neurodegenerative disorders by astrocyte-specific overexpression of TMEM164 in mice10.1038/s42255-023-00887-8 ↗
96. Complement 3+-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia10.1186/s40478-019-0735-1 ↗
97. Transcriptomic diversity of cell types across the adult human brain10.1126/science.add7046 ↗
98. Spatially controlled construction of assembloids using bioprinting10.1038/s41467-023-40006-5 ↗
99. In vitro modeling of the human dopaminergic system using spatially arranged ventral midbrain–striatum–cortex assembloids10.1038/s41592-023-02080-x ↗
100. Staging of brain pathology related to sporadic Parkinson’s disease10.1016/s0197-4580(02)00065-9 ↗